Introduction:

Remote Patient Monitoring (RPM) is reshaping chronic disease management across Europe, as connected health technologies, including wearable sensors, mobile health apps, and cloud-based platforms, enable continuous, real-time monitoring beyond traditional clinical environments. This digital transformation is proving essential in managing long-term conditions like cardiovascular disease, diabetes, chronic respiratory disorders, and neurodegenerative illnesses.

The European RPM market is set for substantial expansion, driven by demographic aging, escalating healthcare costs, the rising incidence of chronic conditions, and strong policy momentum supporting digital health adoption. Valued at approximately USD 2.6 billion in 2024, the market is forecasted to grow to USD 11.4 billion by 2030, at a compound annual growth rate (CAGR) of 28%. As health systems across the region move toward proactive and personalized care models, RPM is emerging as a foundational tool in delivering scalable, data-driven chronic care.

Market Dynamics:

Europe’s RPM market for chronic disease management is gaining strong traction, propelled by rapid technological innovation and evolving healthcare demands. Growth drivers include the increasing burden of chronic illnesses, heightened demand for remote care, and advancements in wearable technologies, IoT, and cloud-based infrastructures. These innovations are streamlining clinical workflows by facilitating real-time patient monitoring, early complication detection, and personalized patient engagement, ultimately lowering hospitalization rates and driving cost efficiencies.

Substantial opportunities lie in broadening RPM applications across conditions such as heart failure, diabetes, COPD, and neurological diseases. The integration of AI and machine learning is enhancing RPM platforms with predictive analytics and targeted interventions. In parallel, expanding government support and reimbursement models are accelerating the adoption of digital health tools. The surge in RPM use for post-acute and home-based care is further unlocking new growth pathways.

Key trends shaping the market include rising focus on data privacy, system interoperability, and the ethical implementation of AI-enhanced RPM tools. There’s a clear movement toward integrating diverse health data—biometric, behavioral, and environmental—to create a more predictive and holistic chronic care approach. Companies like Huma are deploying AI-powered platforms that combine real-time monitoring with clinical decision support, enabling comprehensive remote care pathways. Similarly, Cera Care is leveraging predictive analytics in home-based RPM to merge wearable data with clinical insights, empowering caregivers to intervene early and reduce emergency admissions. As population health management becomes a strategic priority, RPM is emerging as a key enabler of personalized, value-based care models across Europe.

Segment Highlights and Performance Overview:

By Device Type
Wearables lead the device segment, representing around 38% of the market share. Their dominance stems from the ease of real-time, continuous monitoring and growing consumer demand for accessible, user-friendly health tracking tools. Increasing integration with smartphones and healthcare platforms continues to drive adoption, positioning wearables as a cornerstone of RPM in chronic disease management.

By Service Type
Chronic Disease Progression Management holds the largest share within the service segment, capturing roughly 40% of the market. The need for consistent monitoring of conditions such as heart failure, diabetes, and COPD is critical to avoid complications and hospitalizations. RPM solutions that enable ongoing disease tracking empower clinicians to act proactively, improving patient outcomes and reducing system costs.

By Patient Setting
Home-based Patients dominate this segment with approximately 55% market share. The rising preference for care at home, supported by evolving reimbursement structures and advancements in remote monitoring tools, is fueling widespread adoption of RPM in residential settings.

By Chronic Disease Type
Cardiovascular Diseases represent the leading segment, driven by the high prevalence and significant healthcare burden of these conditions. RPM solutions tailored to cardiovascular care allow for ongoing risk monitoring, early intervention, and optimized disease management, making them central to chronic care strategies.

By Business Model
Subscription-based Platforms are gaining ground as healthcare providers and patients favor flexible, scalable solutions with predictable pricing models. These platforms enable consistent patient monitoring, data integration, and platform upgrades without high upfront investment, aligning with broader trends in digital health delivery.

By End Users
Hospitals & Clinics are key adopters of RPM, using these tools to extend care beyond hospital walls, reduce readmissions, and enhance chronic disease outcomes. As clinical settings integrate RPM into patient care pathways, their role in supporting early intervention and long-term monitoring is becoming increasingly critical.

Geographical Analysis:

The Europe Chronic Disease Management via RPM Market is studied across Germany, France, Italy, the United Kingdom, Russia, Spain, the Nordic Countries, Benelux, and the rest of Europe.

The United Kingdom currently leads the European Chronic Disease Management via Remote Patient Monitoring (RPM) market, holding an estimated 25–30% share. This dominance is attributed to its well-established digital health infrastructure, strong NHS-led telehealth initiatives, and favorable reimbursement policies. UK healthcare providers are leveraging RPM to manage cardiovascular conditions, diabetes, and COPD more effectively. The country’s proactive regulatory support continues to position it as a benchmark for digital chronic care management in Europe.

Germany, while second in overall market size, is exhibiting the fastest growth in the European RPM landscape with a projected CAGR of 14–15% through 2030. This rapid expansion is driven by the government’s progressive DiGA program, which reimburses digital health apps and RPM devices. High patient engagement, advanced EHR integration, and hospital-level digitization have created fertile ground for RPM adoption. As the country aggressively modernizes its healthcare delivery, it is emerging as the continent’s most dynamic RPM growth engine.

Competition Landscape:

The competitive environment is marked by a diverse mix of digital health startups, medical technology firms, and established healthcare providers. Players are differentiating through innovation in wearable devices, AI-powered analytics, and integrated care platforms. Strategic alliances with hospitals, insurers, and public health institutions—as well as a strong focus on intuitive, patient-centered design—are proving vital to capturing market share in this fast-evolving sector.

Leading companies profiled in this report include Cera Care, Huma, 52 North Health, Tunstall Healthcare, Luscii, Onera Health, BioSerenity, Implicity, Resilience, Acorai, Aktiia, and Nia Health.

Recent Developments:

• In January 2025, Cera Care raised $150 million to expand its AI-powered home healthcare model, boosting service capacity and clinical trials for individuals over 65. This funding accelerates the use of AI-driven RPM for elderly care, improving access, easing hospital loads, and enhancing outcomes across Europe.
• In March 2024, Aktiia secured CHF 27 million (approximately $30 million) to further develop its cuffless blood pressure monitoring solution. The investment supports the expansion of RPM in cardiovascular care by offering a more comfortable, long-term monitoring alternative for patients managing chronic hypertension.

Segmentation: 

By Device Type:

• Wearables
• Biosensors
• Mobile Health (mHealth) Apps
• Telemedicine & Video Conferencing Tools
• Integrated Monitoring Platforms

By Service Type:

• Preventive Care & Early Detection
• Post-Acute / Transitional Care
• Chronic Disease Progression Management
• Medication Adherence Monitoring
• Emergency Avoidance & Readmission Reduction

By Patient Setting:

• Home-based Patients
• Nursing Homes / Long-term Care Facilities
• Rehabilitation Centers
• Post-discharge (Hospital-at-Home programs)

By Chronic Disease Type:

• Cardiovascular Diseases
• Diabetes
• Chronic Respiratory Diseases
• Kidney Disease (CKD)
• Others

By Business Model:

• Device-as-a-Service (DaaS)
• Subscription-based Platforms
• Integrated Care Solutions (Bundled RPM + Care Coordination)
• Payer-Funded Programs
• Direct-to-Consumer (DTC)

By End User:

• Hospitals & Specialty Clinics
• Home Care Agencies
• Payers (Public & Private Insurers)
• Government / Public Health Systems
• Self-monitoring Patients / Consumer RPM

Companies included in the report:

• Cera Care 
• Huma 
• 52 North Health 
• Tunstall Healthcare
• Luscii 
• Onera Health 
• BioSerenity
• Implicity 
• Resilience 
• Acorai 
• Aktiia
• Nia Health